Kui Cheng

Title: Innovations of Kui Cheng in Inflammatory Disorder Treatments

Introduction

Kui Cheng is an accomplished inventor based in Boulder, CO (US). He has made significant contributions to the field of medical research, particularly in the area of inflammatory disorders. With a total of 2 patents, his work focuses on innovative compounds and methods that target specific receptor complexes involved in inflammation.

Latest Patents

Cheng's latest patents include "Antagonists of the toll-like receptor 1/2 complex" and "Modulators of TLR3/dsRNA complex and uses thereof." The first patent provides compounds, compositions, and methods for treating Toll-like receptor 1/2 complex (TLR1/2) related inflammatory disorders. It discloses small molecules based on the benzotropolone scaffold that can influence downstream signaling. Additionally, it outlines methods for treating subjects with clinical conditions associated with TLR1/2 activation by administering effective amounts of these benzotropolone compounds. The second patent focuses on compounds and compositions that can modulate the formation of the Toll-like receptor 3 (TLR3) and double-stranded RNA (dsRNA) complex, providing methods for their use.

Career Highlights

Cheng is affiliated with the University of Colorado, where he conducts his research and development work. His innovative approaches have garnered attention in the scientific community, contributing to advancements in therapeutic strategies for inflammatory conditions.

Collaborations

Cheng collaborates with various professionals in his field, including his coworker Hang Hubert Yin, who is also a notable figure in the research community.

Conclusion

Kui Cheng's contributions to the field of inflammatory disorder treatments through his innovative patents highlight the importance of research and development in medical science. His work continues to pave the way for new therapeutic options for patients suffering from these conditions.